Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Insulin Action and the Skin
Description
Dr. Joshua Cook, an endocrinologist at Columbia, presented insights on the relationship between insulin action and skin conditions, particularly focusing on obesity's role as a risk factor for several skin diseases. He emphasized that obesity's mechanical and metabolic effects are significant contributors to conditions like psoriasis, which is notably linked to insulin resistance and type 2 diabetes. Cook explained how insulin operates within the body during fasting and fed states, highlighting the consequences of insulin resistance, which leads to hyperinsulinemia and can eventually contribute to diabetes. He pointed out the epidemiological ties between psoriasis and diabetes, noting that intensive treatment aimed at reducing insulin levels, such as weight loss, often positively correlates with improved psoriasis severity. Additionally, Cook hypothesized about potential localized effects of insulin signaling in psoriasis lesions, suggesting that these areas might be more responsive to insulin than other tissues, which could open new avenues for treatment. He concluded by calling for more research to better understand these mechanisms and their implications for treating inflammatory skin diseases.
View moreConclusions
- Obesity is a significant risk factor for various skin diseases due to both mechanical and metabolic complications.
- Inflammatory skin diseases, including psoriasis, may be linked to obesity and metabolic syndrome through insulin resistance.
- Weight loss can improve skin disease activity in patients with psoriasis, indicating a connection between metabolic health and skin conditions.
- Pioglitazone, an insulin sensitizer, has shown to improve psoriasis severity in small clinical trials.
- Insulin resistance may be involved in the pathogenesis of psoriasis and other inflammatory skin diseases, making it an important consideration in dermatology.
- Improving insulin sensitivity via lifestyle changes or medications correlates with better psoriasis outcomes.
- Psoriasis patients exhibit higher rates of insulin resistance compared to matched controls.
- The insulin signaling pathway may play a direct role in psoriasis lesions, suggesting potential therapeutic targets to improve treatment outcomes.
- Hirt PA, et al. J Am Acad Dermatol 81, 2019.
- Page MM & Johnson JD. Trends Endocrinol Metab 29, 2018.
- Armstrong AW, et al. JAMA Dermatol 149, 2013.
- Gyldenløve M, et al. J Am Acad Dermatol 72, 2015.
- Cook JR, et al. Nat Metab 5, 2023.
- Norton L, et al. Metabolism 129, 2022.
- Ho JH, et al. EDM Case Rep 17, 2021.
- Parker VER & Semple RK. Eur J Endocrinol 169, 2013.
- Taniguchi CM, et al. Nat Rev Mol Cell Biol 7, 2006.
- Camisa C, et al. CCJM 57, 1990.
- Field S, et al. Clin Exp Dermatol 33, 2008.
- Goh CL. Australas J Dermatol 28, 1987.
- Moore AF, et al. Diabetes Care 31, 2008.
- Reubi JC, Hunziker T. Arch Dermatol Res 282, 1990.
- Chamcheu JC, et al. Acta Derm Venereol 96, 2016.
- Chamcheau JC, et al. Antioxid Redox Signal 26, 2017.
- Mercurio L, et al. J Derm Sci 115, 2024.